Company Filing History:
Years Active: 2011-2012
Title: Tamas Rujan: Innovator in Cancer Research
Introduction
Tamas Rujan is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of cancer research, particularly in the area of breast cancer treatment. With a focus on innovative methods for predicting treatment responses, Rujan has been awarded 2 patents for his groundbreaking work.
Latest Patents
Rujan's latest patents include a method for determining the risk of relapse of breast cancer following tamoxifen adjuvant therapy. This invention relates to modified and genomic sequences, oligonucleotides, and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA. It also provides a method for predicting the response of a subject with a cell proliferative disorder of the breast tissues to endocrine treatment. Another significant patent is a method for determining the methylation pattern of a polynucleic acid. This method involves preparing a solution of polynucleic acid fragments, coupling them with detectable substances, and using a DNA microarray for hybridization and detection.
Career Highlights
Tamas Rujan is currently associated with Epigenomics AG, a company focused on developing innovative cancer diagnostics. His work has been instrumental in advancing the understanding of cancer biology and improving treatment strategies.
Collaborations
Rujan has collaborated with esteemed colleagues such as Thomas Koenig and John Foekens. These partnerships have further enhanced the impact of his research in the scientific community.
Conclusion
Tamas Rujan's contributions to cancer research through his innovative patents and collaborations highlight his commitment to improving patient outcomes. His work continues to pave the way for advancements in cancer diagnostics and treatment.